%0 Journal Article %A Nicola Smith %A Owen Williams %A Lucia Ricciardi %A Francesca Morgante %A Thomas R Barrick %A Mark Edwards %A Christian Lambert %T Predicting Future Cognitive Impairment in De Novo Parkinson’s Disease Using Clinical Data and Structural MRI %D 2021 %R 10.1101/2021.08.13.21261662 %J medRxiv %P 2021.08.13.21261662 %X BACKGROUND Parkinson’s disease is the second most common neurodegenerative condition and associated with increasing cognitive dysfunction as the disease progresses. However, subtle cognitive deficits can be detected at diagnosis in 42% of individuals, suggesting that damage may already be present. Our aim was to determine clinical and structural differences in those recently diagnosed with PD who later develop cognitive impairment, and whether these changes predict future cognitive decline.METHODS Clinical and imaging data was acquired from the Parkinson’s Progression Markers Initiative for 318 individuals with a diagnosis of Parkinson’s disease and baseline 3T T1-weighted MRI. The cohort was divided according to cognitive status over follow-up, with 9 individuals developing Parkinson’s disease dementia, 102 developing mild cognitive impairment and 207 remaining cognitively unaffected.FINDINGS At baseline, those who went on to develop cognitive impairment (mild cognitive impairment or dementia) were older with more severe motor and non-motor symptoms (anosmia, rapid eye movement sleep behaviour disorder, depression). Grey matter loss was present in those destined for Parkinson’s disease dementia in the precuneus, hippocampi, primary olfactory cortex, lingual gyrus, temporal cortex and cerebellum. Those who later developed mild cognitive impairment had an attenuated but similar pattern of grey matter loss in the temporal lobe, lingual gyrus and cerebellum. Using support vector machines with a feature selection step, future cognitive impairment could be predicted using 11 clinical variables (AUC = 0.81), structural imaging (AUC = 0.72) or a combination of these two modalities (AUC = 0.85). These models more accurately predicted those who developed dementia (subgroup sensitivity 100%).INTERPRETATION Significant abnormalities in cortical structure is present at least three years before dementia manifests in Parkinson’s disease, with associated differences in clinical profiles. Combining this data provides a technique to accurately identify future cognitive impairment, providing a non-invasive way to stratify individuals early on.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCL is funded by a Medical Research Council grant (MR/R006504/1), and was also supported by the Guarantors of Brain Post Doctoral Fellowship for this work. ME receives research support from a Medical Research Council Grant (MR/M02363X/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Progression in Parkinson's Markers Initiative (PPMI) is an ongoing international initiative sponsored by the Michael.J.Fox foundation (ClinicalTrials.gov Identifier: NCT01141023). De-identified data from this study has been made publically available via https://www.ppmi-info.org/access-data-specimens/download-data/. Re-use of this data by qualified researchers not involved in the PPMI study, such as this work, is allowed subject to approval from the PPMI investigators. A copy of this manuscript was reviewed by the PPMI board, as per their data use agreement (https://www.ppmi-info.org/documents/ppmi-data-use-agreement.pdf) and publication policy (https://www.ppmi-info.org/documents/ppmi-publication-policy.pdf).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the Progression in Parkinson's Markers Initiative was used for this work %U https://www.medrxiv.org/content/medrxiv/early/2021/08/18/2021.08.13.21261662.full.pdf